Valvular & structural heart diseaseMeta-analysis
SGLT-2 Inhibitors and Outcomes After Transcatheter Aortic Valve Implantation
- meta-analysis
- systematic search
- randomized controlled trials (RCTs) and observational studies
- adjusted HRs and risk ratios pooled
Authors' conclusion
This meta-analysis suggests that peri-operative SGLT-2i use was associated with lower cardiovascular events post-TAVI albeit with low certainty due to predominance of observational studies. These findings are hypothesis generating rather than causal inference. Future clinical trials are warranted.
Study context
- Population
- Patients undergoing transcatheter aortic valve implantation (TAVI)Six studies (1 RCT, 5 cohorts)
- Participants
- 35,075 patients
- Comparison
- association between sodium glucose co-transporter 2 inhibitor (SGLT-2i) use and clinical outcomes in patients undergoing TAVI
Pooled result
major adverse cardiovascular events
Pooled hazard ratio
0.65
95% CI 0.44–0.95
P = 0.03
SGLT-2i use
pooled HR 0.65 (95% CI 0.44–0.95); P = 0.03
As reported in the abstract
Further pooled results
heart failure hospitalization
| Comparison | pooled HR (95% CI) | P value | |
|---|---|---|---|
| SGLT-2i use · I2 = 59%; significantly lower risk with SGLT-2i use | 0.58 (0.40–0.86) | P = 0.007 | |
| 0.512Pooled hazard ratio (log scale) |
all-cause mortality
| Comparison | pooled HR (95% CI) | P value | |
|---|---|---|---|
| SGLT-2i use · I2 = 75%; significantly lower risk with SGLT-2i use | 0.71 (0.55–0.91) | P = 0.007 | |
| 0.512Pooled hazard ratio (log scale) |
cardiovascular death
| Comparison | pooled risk ratio (95% CI) | P value | |
|---|---|---|---|
| SGLT-2i use · I2 = 36%; significantly lower risk with SGLT-2i use | 0.55 (0.34–0.89) | P = 0.01 | |
| 0.20.5125Pooled risk ratio (log scale) |
GRADE certainty
- The Grading of Recommendations Assessment, Development, and Evaluation assessment was downgraded due to heterogeneity, potential bias, and nonrandomized design of studies
Original publication
SGLT-2 Inhibitors and Outcomes After Transcatheter Aortic Valve Implantation. JACC Adv. Published 23 June 2026. doi:10.1016/j.jacadv.2026.102884
Summarised from the published abstract; every number is checked against it